Saturn V Capital Management fully exited its position in Ocular Therapeutix, selling 1.5 million shares for approximately $14.34 million in Q1 2026. The exit comes as Ocular faces investor skepticism following lighter-than-expected Q1 revenue of $10.8 million and widened net losses of $88.6 million, despite positive Phase 3 clinical data for its retinal disease candidate AXPAXLI. The company maintains a strong cash position of $666.7 million with runway into 2028, but must now prove it can commercialize its pipeline.

Ocular Therapeutix announced an Investor Day scheduled for June 17, 2026, in New York City with virtual access. The company also reported additional positive Week 52 data from its landmark SOL-1 Phase 3 trial of AXPAXLI in wet AMD, demonstrating robust disease control with sustained durability and a median time of 39 weeks for CSFT control.

Ocular Therapeutix announced it will present topline results from its SOL-1 Phase 3 superiority trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration on February 17, 2026, with detailed data to follow at the Macula Society Annual Meeting. The company is advancing its investigational retinal disease treatment candidate through clinical development.

The global corticosteroids market is projected to grow from USD 6.24 billion in 2025 to USD 8.45 billion by 2031 at a CAGR of 5.18%, driven by rising chronic diseases like asthma and COPD. However, safety concerns from prolonged usage and a shift toward biologics and localized therapies present significant challenges. Innovations in drug delivery systems and extended-release formulations are reshaping the market.

Ocular Therapeutix (NASDAQ: OCUL) shares surged approximately 21% in premarket trading after reports indicated that Sanofi is preparing a revised and higher takeover bid for the company. Sanofi had previously offered $16 per share in September, which was rejected by Ocular's board. The potential acquisition would give Sanofi exposure to the wet age-related macular degeneration market through Ocular's drug candidate Axpaxli, which is in late-stage development with key clinical data expected in 2026-2027.

Ocular Therapeutix has granted inducement equity awards to eight newly hired non-executive employees, including stock options and restricted stock units representing shares of the company's common stock.

Ocular Therapeutix granted inducement equity awards to a new non-executive employee, consisting of a stock option and restricted stock unit award. The company continues to develop its retinal disease treatment pipeline, with AXPAXLI in Phase 3 clinical trials for wet age-related macular degeneration.

Ocular Therapeutix reported Q2 2025 financial results with declining revenue, increased research spending, and ongoing clinical trials for eye disease treatments. The company faces reimbursement challenges but continues to advance its pipeline, particularly the AXPAXLI ocular implant for wet AMD.

Ocular Therapeutix, a biopharmaceutical company, announced the closing of enrollment for its second registrational trial, SOL-R, evaluating AXPAXLI for the treatment of wet age-related macular degeneration. The trial is the largest retinal TKI trial to date, with plans to randomize at least 555 subjects.

Ocular Therapeutix, a biopharmaceutical company, announced its participation in two investor conferences in April 2025, where it will present its product candidate AXPAXLI for wet age-related macular degeneration and provide updates on its pipeline.

Ocular Therapeutix, a biopharmaceutical company, announced that it has granted inducement awards to a newly hired employee, including a stock option and a restricted stock unit award.

Ratings for Ocular Therapeutix (NASDAQ:OCUL) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 2 2 1 0 0 3M Ago 0 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.17, a high estimate of $24.00, and a low estimate of $7.00. A 0.49% drop is evident in the current average compared to the previous average price target of $16.25. Deciphering Analyst Ratings: An In-Depth Analysis The standing of Ocular Therapeutix among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Yi Chen HC Wainwright & Co. Maintains Buy $14.00 $14.00 Yi Chen HC Wainwright & Co. Lowers Buy $14.00 $16.00 Jonathan Wolleben JMP Securities Lowers Market Outperform $22.00 $24.00 Tara Bancroft TD Cowen Lowers Hold $7.00 $11.00 Yi Chen HC Wainwright & Co. Maintains Buy $16.00 - Jonathan Wolleben JMP Securities Maintains Market Outperform $24.00 - Key Insights: Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it ...Full story available on Benzinga.com